ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "autoimmune diseases"

  • Abstract Number: 0198 • ACR Convergence 2024

    COVID-19 Vaccination and Hospitalization Rates Differ Between People with Diagnosed Immune Mediated Inflammatory Disease and the General Population: A Population-based Study

    Carol Hitchon1, Carole Taylor1, Charles N Bernstein1, Christine Peschken1, J. Antonio Avina-Zubieta2, Sasha Bernatsky3, Gil Kaplan4, Diane Lacaille2, Jessica Widdifeild5 and RuthAnn Marrie1, 1University of Manitoba, Winnipeg, MB, Canada, 2Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, 3Research Institute of the McGill University Health Centre, Montreal, QC, Canada, 4University of Calgary, Calgary, AB, Canada, 5University of Toronto, Toronto, ON, Canada

    Background/Purpose: People with immune mediated inflammatory diseases (IMIDs) are at greater risk of severe Coronavirus disease (COVID-19). Vaccination reduces COVID-19 severity however, vaccine uptake may…
  • Abstract Number: 0304 • ACR Convergence 2024

    Severe Infection in COVID-19 Vaccinated Patients with Systemic Autoimmune Rheumatic Diseases on B Cell Targeted Therapies: Association with Neutrophil-lymphocyte Ratio

    doryan Garcia Olivas1, Judith Hernández Sánchez1, luis Bausá Gimeno1, Javier Nóvoa Medina1, Sergio Machín1, Maria Ángeles Acosta-Mérida1, Diana Botello-Corzo1, daniel Batista Perdomo1, José Ángel Hernández Beriain2 and Beatriz Tejera Segura1, 1Rheumatology Department. Hospital Universitario Insular de Gran Canaria, las Palmas, Spain, 2Rheumatology Department. Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran C, Spain

    Background/Purpose: Patients with systemic autoimmune rheumatic diseases (SARDs) are at higher risk of general infection due to the presence of comorbidities, underlying disease activity, and…
  • Abstract Number: 0436 • ACR Convergence 2024

    Family Planning in Rheumatology: A Single Center Quality Improvement Project

    Sara Heard, Elena Cravens, Jeanne Gosselin and Juvena Hitt, University of Vermont Medical Center, Burlington, VT

    Background/Purpose: Pregnancy in patients with rheumatologic disease can lead to serious maternal and fetal complications. Multinational surveys have shown that medical providers often fail to…
  • Abstract Number: 0678 • ACR Convergence 2024

    Patients with Interstitial Lung Disease Due to Systemic Sclerosis or Rheumatoid Arthritis Need Monitoring More Frequently Than Annually

    Oliver Distler1, Margarida Alves2, Gerrit Toenges3 and Anna-Maria Hoffmann-Vold4, 1Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland, 2Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim, Germany, 3Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, 4Oslo University Hospital, Oslo, Norway

    Background/Purpose: There is no consensus on the frequency of monitoring of patients with autoimmune disease-related interstitial lung diseases (ILDs), but a frequency of 1 year…
  • Abstract Number: 0835 • ACR Convergence 2024

    Effective Engineering of CD8+ T Cells from Autoimmune Disease Patients Utilizing a CD8-Targeted Lipid NanoparticleEncoding an Anti-CD19 CAR mRNA(CPTX2309)

    Yan Zhang1, Brittany Ross1, Diana Galvan1, Yanjie Bao1, Daiki Matsuda1, Shaun Grosskurth1, Iago Pinal-Fernandez2, Maria Casal-Dominguez3, Gregor Adams1, Michael Rosenzweig1, Ramin Farzaneh-Far1, Priya Karmali1, Adrian Bot1, Andrew Mammen2 and Haig Aghajanian1, 1Capstan Therapeutics, San Diego, CA, 2NIH, Bethesda, MD, 3NIH, Bathesda, MD

    Background/Purpose: Ex vivo chimeric antigen receptor (CAR) T cell therapies have revolutionized cancer treatment and are demonstrating durable clinical efficacy in various autoimmune disease (AID)…
  • Abstract Number: 0908 • ACR Convergence 2024

    Clinical Characteristics of Patients with High SLE-specific and High Multitrait Polygenic Risk – an Investigation of SLE Risk Loci

    Nina Oparina1, Sarah Reid2, Ahmed Sayadi3, Maija-Leena Eloranta4, Martina Frodlund5, Karoline Lerang6, Andreas Jönsen7, Solbritt Rantapaa-Dahlqvist8, Anders Bengtsson7, Anna Rudin9, Øyvind Molberg10, Christopher Sjowall11, Lars Rönnblom4 and Dag Leonard4, 1UU, Uppsala, Sweden, 2Uppsala University, Medical Sciences, Uppsala, Sweden, 3Uppsala, Uppsala, Sweden, 4Uppsala University, Uppsala, Sweden, 5Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection/Rheumatology, Linköping University, Linköping, Sweden, 6Oslo University, Oslo, Norway, 7Lund University, Lund, Sweden, 8Umeå University, Umeå, Sweden, 9Institute of Medicine, University of Gothenburg, Gothenburg, Sweden, 10Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, 11Linköping University, Linköping, Sweden

    Background/Purpose: Heritability of SLE is high and more than 200 genetically associated SLE risk loci were identified. Part of them  are specific and associate with…
  • Abstract Number: 0988 • ACR Convergence 2024

    Antinuclear Antibody Positivity and Its Diagnostic Implications for Rheumatic Diseases in Dermatology Patients: A Comprehensive Single Center Analysis

    Yunjung Choi1, Myeung-Su Lee2 and Wan-Hee Yoo3, 1Jeonbuk National University Medical School, Deokjin-gu, Jeollabuk-do, Republic of Korea, 2Wonkwang University Hospital, Iksan, South Korea, 3CHONBUK NATIONAL UNIVERSITY HOSPITAL, JEONJU, Republic of Korea

    Background/Purpose: Cutaneous manifestations are common in rheumatic diseases and can be early indicators. This study investigates the prevalence of rheumatic diseases diagnosed through ANA (Antinuclear…
  • Abstract Number: 1141 • ACR Convergence 2024

    Defining a Novel Type of Myositis: Immune Mediated Megaconial Myopathy (IMMM)

    Teerin Liewluck1, Ashley Santilli2, Oliver Ni3, Margherita Milone2, Duygu Selcen2, Anahit Mehrabyan4, Arjun Seth5, Christine Hsieh5, Wasim Raslan6, Moayd Alkhalifah6, Raed Alenezi6, Stefan Nicolau7 and Pannathat Soontrapa8, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic-Rochester, Rochester, MN, 3Hennepin Healthcare, Minneapolis, MN, 4University of North Carolina, Chapel Hill, NC, 5Northwestern University, Chicago, IL, 6Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia, 7Nationwide Children’s Hospital, Columbus, OH, 8Siriraj Hospital, Mahidol University, Bangkok, Thailand

    Background/Purpose: To describe a novel type of myositis, immune mediated megaconial myopathy (IMMM),  pathologically characterized by giant mitochondria (megaconia).Methods: We reviewed the Mayo Clinic Muscle…
  • Abstract Number: 1420 • ACR Convergence 2024

    Alignment Between Rheumatology and Neurology of Nomenclature for Peripheral Nervous System Neuropathies

    Ghaith Noaiseh1, George Sarka2, Anahita Deboo3, Arun Varadhachary4, Robert Fox5, Matthew Baker6, Stamatina Danielides7, Eduardo de Sousa8, Julie Frantsve Hawley9, Brent Goodman10, Katherine Hammitt9, Jennifer King11, Steven Mandel12, Pantelis Pavlakis13, Daniel Wallace14, Robert Hal Scofield15, Nancy Carteron16 and Steven Carsons17, 1University of Kansas Medical Center, Kansas City, KS, 2UCLA, Laguna Hills, CA, 3Temple University, Philadelphia, 4Washington University in St. Louis, St. Louis, MO, 5Rheumatology Clinic, San Diego, CA, 6Stanford University, Menlo Park, CA, 7Vcu, Glen Allen, VA, 8Mercy, Moore, OK, 9Sjogren's Foundation, Reston, VA, 10Mayo Clinic, Scottsdale, AZ, 11UCLA, Los Angeles, CA, 12Hofstra, Hempstead, 13Hospital for Special Surgery, New York, NY, 14Cedars Sinai Medical Center, Studio City, CA, 15Oklahoma Medical Research Foundation, Oklahoma City, OK, 16University of California, Berkeley & San Francisco, Angwin, CA, 17NYU Long Island School of Medicine, Mineola, NY

    Background/Purpose: The Sjögren’s Foundation Clinical Practice Guidelines for Peripheral Nervous System (PNS) diagnosis, management and treatment in Sjögren’s brought to the fore a major issue…
  • Abstract Number: 1590 • ACR Convergence 2024

    Milder ILD with Preserved Lung Function Significantly Contributes to Respiratory Caused Mortality in SSc

    Anna-Maria Hoffmann-Vold1, Håvard Fretheim1, Emily Langballe2, Hilde Jenssen Bjørkekjær3, Henriette Didriksen1, Phuong Phuong Diep4, Anna Helena Andersson1, Ragnar Gunnarsson1, Michael T Durheim1, Torhild Garen1, Øyvind Midtvedt5, Trond Mogens Aaløkken6, Øyvind Molberg7 and Oliver Distler8, 1Oslo University Hospital, Oslo, Norway, 2Oslo University Hospital, Department of Rheumatology, Oslo, Norway, 3Department of Rheumatology, Hospital of Southern Norway, Kristiansand, Kristiansand, Norway, 4Oslo University Hospital, Department of Respiratory Disease, Oslo, Norway, 5Oslo University Hospital, Oslo, Oslo, Norway, 6Medicine, Oslo, Norway, Oslo, Norway, 7Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, 8Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland

    Background/Purpose: Interstitial lung disease (ILD) is the main cause of death in systemic sclerosis (SSc). While impaired lung function with forced vital capacity (FVC) <…
  • Abstract Number: 1740 • ACR Convergence 2024

    Performance of Large Language Models in Rheumatology Board-Like Questions: Accuracy, Quality, and Safety

    Jaime Flores Gouyonnet1, Mariana Gonzalez-Trevino1, Cynthia Crowson1, Ryan Lennon1, Alain Sanchez-Rodriguez2, Gabriel Figueroa-Parra3, Elena Joerns4, Bradly Kimbrough5, Maria Cuellar-Gutierrez1, Erika Navarro-Mendoza1 and Ali Duarte-Garcia1, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic College of Medicine and Science, Rochester, MN, 3Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, 4Mayo Clinic, Rochester, 5Mayo Clinic Rochester, Rochester, MN

    Background/Purpose: Large language models (LLMs) are increasingly becoming a common source of information for clinicians. We aimed to evaluate the accuracy, quality, and safety of…
  • Abstract Number: 1833 • ACR Convergence 2024

    Immune Complexes of Antibodies Directed to Angiotensin Receptor type-1 and Extracellular Vesicles Are Unique Modulators Contributing to Systemic Sclerosis

    Alexander Maximilian Hackel1, Marieke Leiber1, Maike Winziers1, Gabriela Riemekasten2 and Reza Akbarzadeh1, 1Department of Rheumatology and Clinical Immunology, University of Lübeck, Lübeck, Germany, 2University of Lübeck, Department of Rheumatology and Clinical Immunology, Lübeck, Germany

    Background/Purpose: Antibodies (Abs) directed against the angiotensin II type-1 receptor (AT1R) and extracellular vesicles (EVs) derived from systemic sclerosis (SSc) patients have the potential to…
  • Abstract Number: 1927 • ACR Convergence 2024

    Ethnic and Racial Minorities in Clinical Trials for Autoimmune Connective Tissue Disease Therapeutic Agents

    Connor Buechler, Lindsey Wanberg, Cody Rasner, Nicole Theis-Mahon, Dawn Hackman and David Pearson, University of Minnesota, Minneapolis, MN

    Background/Purpose: Black, Indigenous, and people of color (BIPOC) experience greater morbidity and mortality from autoimmune connective tissue diseases (AICTDs); thus, equitable access to randomized controlled…
  • Abstract Number: 2055 • ACR Convergence 2024

    Demographic and Ocular Characteristics of Scleritis Patients with Systemic Rheumatologic Disease in the IRIS® Registry (Intelligent Research in Sight)

    Laura Kopplin1 and Karen Armbrust2, 1Department of Ophthalmology and Visual Sciences, University of Wisconsin-Madison, Madison, WI, 2Department of Ophthalmology and Visual Neurosciences, University of Minnesota, Minneapolis, MN

    Background/Purpose: Scleritis is a rare, potentially vision threatening ocular inflammatory disease.  30-40% of scleritis is associated with systemic autoimmune diseases with reports of worse visual…
  • Abstract Number: 2326 • ACR Convergence 2024

    Development and Evaluation of a Machine Learning Model for the Early Identification of Psoriatic Arthritis

    Michael Dreyfuss1, Dan Riesel2, Guy Shalev2, Benjamin Getz3, Or Ramni2, Yonatan Jenudi4, Dimid Duchovny2, Daniel Underberger5, Shlomit Steinberg-Koch2, Douglas White6 and Elena Myasoedova7, 1Predicta Med, Ramat Gan, Israel, 2Predicta Med Analytics Ltd., Ramat Gan, Israel, 3CTO, Ramat Gan, Israel, 4[email protected], Ramat Gan, Israel, 5Predicta Med Analytics Ltd., Bridgeport, CT, 6Gundersen Health System, Onalaska, WI, 7Mayo Clinic, Rochester, MN

    Background/Purpose: Delays in diagnosis of psoriatic arthritis (PsA) are associated with indolent and non-specific signs and symptoms, and often result in physical impairment and poorer…
  • « Previous Page
  • 1
  • …
  • 28
  • 29
  • 30
  • 31
  • 32
  • …
  • 101
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology